RNA-based vaccine platform that dampens excessive innate immune responses to improve tolerability of nucleic acid medicines.
ExcepGen's RNAx platform is an mRNA-encoded protein that modulates cellular responses to RNA and lipid nanoparticles, aiming to reduce the overactive innate immune response associated with nucleic acid vaccines. The platform complements existing mRNA vaccine advances in capping, delivery, and non-natural nucleosides by addressing the cellular response to nucleic acids. Core initiatives include self-amplifying and trans-amplifying mRNA vaccines. ExcepGen RNAx is a product of Excepgen.